The STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman Syndrome

OBJECTIVE: To evaluate safety and tolerability and exploratory efficacy end points for gaboxadol (OV101) compared with placebo in individuals with Angelman syndrome (AS). METHODS: Gaboxadol is a highly selective orthosteric agonist that activates δ-subunit–containing extrasynaptic γ-aminobutyric aci...

Descripción completa

Detalles Bibliográficos
Autores principales: Bird, Lynne M., Ochoa-Lubinoff, Cesar, Tan, Wen-Hann, Heimer, Gali, Melmed, Raun D., Rakhit, Amit, Visootsak, Jeannie, During, Matthew J., Holcroft, Christina, Burdine, Rebecca D., Kolevzon, Alexander, Thibert, Ronald L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055330/
https://www.ncbi.nlm.nih.gov/pubmed/33443117
http://dx.doi.org/10.1212/WNL.0000000000011409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055330/
https://www.ncbi.nlm.nih.gov/pubmed/33443117
http://dx.doi.org/10.1212/WNL.0000000000011409

Ejemplares similares